RBS comments from bio conf
"Invion (IVX)
The presentation from CEO Greg Collier was a standout presentation. Key takeaways were interim results from the smoking cessation trial due late CY13 and a new program for an inhaled asthma product.
This is a well managed company with clear partnering opportunities on successful clinical results."
http://www.rbsmorgans.com/Blog/2013/October/Notable-notes-from-Australia-Biotech.aspx
RBS comments from bio conf"Invion (IVX)The presentation from CEO...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
-0.005(3.85%) |
Mkt cap ! $10.59M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.0¢ | 12.0¢ | $16.81K | 134.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14995 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 12200 | 2 |
View Market Depth
| Last trade - 15.37pm 24/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |